Lexaria Bioscience Corp LEXX

Alternate Symbol(s): LEXXW

Healthcare

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

NDAQ:LEXX - Post by User

Lexaria Bioscience Corp > Lexaria Bioscience Corp. (NASDAQ: LEXX) - A Zacks Update

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Jul 11, 2023 9:00pm

146 Views

Post# 35536626

Lexaria Bioscience Corp. (NASDAQ: LEXX) - A Zacks Update

Just In: $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) - A Zacks UpdateLexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six addi...LEXX - Lexaria Bioscience Corp. (NASDAQ: LEXX) - A Zacks Update

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale